A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men
The synthetic hexapeptide growth hormone-releasing peptide (GHRP)-2 specifically stimulates GH release in man. To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 d...
Gespeichert in:
| Veröffentlicht in: | European journal of endocrinology 1998-10, Vol.139 (4), p.395-401 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 401 |
|---|---|
| container_issue | 4 |
| container_start_page | 395 |
| container_title | European journal of endocrinology |
| container_volume | 139 |
| creator | NIJLAND, E. A STRASBURGER, C. J POPP-SNIJDERS, C VAN DER WAL, P. S VAN DER VEEN, E. A |
| description | The synthetic hexapeptide growth hormone-releasing peptide (GHRP)-2 specifically stimulates GH release in man. To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days. Every day blood samples were taken to determine GH, IGF-I, IGF-binding protein (IGFBP)-3 and osteocalcin levels. On days 1,3 and 5, GH was measured at -20,0,20,40,60,90,120 and 180 min using an immunometric and an immunofunctional assay. Mean-/+S.D). peak GH concentrations were 83+/-31, 59+/-22 and 51+/-13 microg/l on days 1, 3 and 5 respectively. Mean+/-S.D. areas under the curve for days 1, 3 and 5 were 6366+/-2514, 3987 +/- 1418 and 3392+/-1215 mU/l per min. Despite the maintained GH release, analysis of variance revealed that significant response attenuation occurred (P < 0.01). Mean serum IGF-I concentration did not increase after a 5 day treatment with GHRP-2. Mean basal levels were 22, 25,23,25,23,24 nmol/l measured on days 1 to 6. However, osteocalcin, another serum marker of GH activity in tissue, increased significantly from 3.2+/-1.0 to 4.2+/-0.4 microg/l (mean+S.D.) (P< 0.01). |
| doi_str_mv | 10.1530/eje.0.1390395 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70066418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70066418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-2492d93c1ba3d80ead402260bf43538077b2eee94fa0ea276718c3adc1bbceb33</originalsourceid><addsrcrecordid>eNo9UU1v1DAUtBCoLIUjRyQfEDcXJ_bm41hVQCtV4gISt-jFeel6cezFz26V_8iPwu0uPXnkmXnz7GHsfSUvqq2Sn3GPFwWqXqp--4JtKt32ounUr5dsIzuphW60es3eEO2lrAqWZ-ys72rZVNsN-3vJZ3uPfIKVp4iQFvSJP9i0K1fWrZzyaHICjyETt36PJtngiYeZ38XwUHS7EJfgUUR0CGT9HT_gIdkJRc0NZELiEelQTMghJfQZHkdw8BOfQmF9SJySXbKDhCWDsrNeOPsb_0fMYFKI4oYTmohPbuv5DsGl3crXkEtoWfwtezWDI3x3Os_Zz69fflxdi9vv326uLm-FUbpJotZ9PfXKVCOoqZMIk5Z13chx1mqrOtm2Y42IvZ6hkHXbtFVnFEzFMBoclTpnn45zDzH8yUhpWCwZdO74TUMrZdPoqitCcRSaGIgizsMh2gXiOlRyeGxvKO0NBR7bK_oPp8F5XHB6Vp_qKvzHEw9kwM0RvLH0LKt1eYVq1T9ONqj4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70066418</pqid></control><display><type>article</type><title>A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>NIJLAND, E. A ; STRASBURGER, C. J ; POPP-SNIJDERS, C ; VAN DER WAL, P. S ; VAN DER VEEN, E. A</creator><creatorcontrib>NIJLAND, E. A ; STRASBURGER, C. J ; POPP-SNIJDERS, C ; VAN DER WAL, P. S ; VAN DER VEEN, E. A</creatorcontrib><description>The synthetic hexapeptide growth hormone-releasing peptide (GHRP)-2 specifically stimulates GH release in man. To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days. Every day blood samples were taken to determine GH, IGF-I, IGF-binding protein (IGFBP)-3 and osteocalcin levels. On days 1,3 and 5, GH was measured at -20,0,20,40,60,90,120 and 180 min using an immunometric and an immunofunctional assay. Mean-/+S.D). peak GH concentrations were 83+/-31, 59+/-22 and 51+/-13 microg/l on days 1, 3 and 5 respectively. Mean+/-S.D. areas under the curve for days 1, 3 and 5 were 6366+/-2514, 3987 +/- 1418 and 3392+/-1215 mU/l per min. Despite the maintained GH release, analysis of variance revealed that significant response attenuation occurred (P < 0.01). Mean serum IGF-I concentration did not increase after a 5 day treatment with GHRP-2. Mean basal levels were 22, 25,23,25,23,24 nmol/l measured on days 1 to 6. However, osteocalcin, another serum marker of GH activity in tissue, increased significantly from 3.2+/-1.0 to 4.2+/-0.4 microg/l (mean+S.D.) (P< 0.01).</description><identifier>ISSN: 0804-4643</identifier><identifier>EISSN: 1479-683X</identifier><identifier>DOI: 10.1530/eje.0.1390395</identifier><identifier>PMID: 9820615</identifier><language>eng</language><publisher>Colchester: Portland Press</publisher><subject>Adult ; Biological and medical sciences ; Hormones. Endocrine system ; Human Growth Hormone - blood ; Humans ; Hydrocortisone - blood ; Insulin-Like Growth Factor Binding Protein 3 - blood ; Insulin-Like Growth Factor I - metabolism ; Kinetics ; Male ; Medical sciences ; Oligopeptides - administration & dosage ; Oligopeptides - pharmacology ; Osteocalcin - blood ; Pharmacology. Drug treatments ; Prolactin - blood</subject><ispartof>European journal of endocrinology, 1998-10, Vol.139 (4), p.395-401</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-2492d93c1ba3d80ead402260bf43538077b2eee94fa0ea276718c3adc1bbceb33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2426037$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9820615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NIJLAND, E. A</creatorcontrib><creatorcontrib>STRASBURGER, C. J</creatorcontrib><creatorcontrib>POPP-SNIJDERS, C</creatorcontrib><creatorcontrib>VAN DER WAL, P. S</creatorcontrib><creatorcontrib>VAN DER VEEN, E. A</creatorcontrib><title>A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men</title><title>European journal of endocrinology</title><addtitle>Eur J Endocrinol</addtitle><description>The synthetic hexapeptide growth hormone-releasing peptide (GHRP)-2 specifically stimulates GH release in man. To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days. Every day blood samples were taken to determine GH, IGF-I, IGF-binding protein (IGFBP)-3 and osteocalcin levels. On days 1,3 and 5, GH was measured at -20,0,20,40,60,90,120 and 180 min using an immunometric and an immunofunctional assay. Mean-/+S.D). peak GH concentrations were 83+/-31, 59+/-22 and 51+/-13 microg/l on days 1, 3 and 5 respectively. Mean+/-S.D. areas under the curve for days 1, 3 and 5 were 6366+/-2514, 3987 +/- 1418 and 3392+/-1215 mU/l per min. Despite the maintained GH release, analysis of variance revealed that significant response attenuation occurred (P < 0.01). Mean serum IGF-I concentration did not increase after a 5 day treatment with GHRP-2. Mean basal levels were 22, 25,23,25,23,24 nmol/l measured on days 1 to 6. However, osteocalcin, another serum marker of GH activity in tissue, increased significantly from 3.2+/-1.0 to 4.2+/-0.4 microg/l (mean+S.D.) (P< 0.01).</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Hormones. Endocrine system</subject><subject>Human Growth Hormone - blood</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Insulin-Like Growth Factor Binding Protein 3 - blood</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - pharmacology</subject><subject>Osteocalcin - blood</subject><subject>Pharmacology. Drug treatments</subject><subject>Prolactin - blood</subject><issn>0804-4643</issn><issn>1479-683X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UU1v1DAUtBCoLIUjRyQfEDcXJ_bm41hVQCtV4gISt-jFeel6cezFz26V_8iPwu0uPXnkmXnz7GHsfSUvqq2Sn3GPFwWqXqp--4JtKt32ounUr5dsIzuphW60es3eEO2lrAqWZ-ys72rZVNsN-3vJZ3uPfIKVp4iQFvSJP9i0K1fWrZzyaHICjyETt36PJtngiYeZ38XwUHS7EJfgUUR0CGT9HT_gIdkJRc0NZELiEelQTMghJfQZHkdw8BOfQmF9SJySXbKDhCWDsrNeOPsb_0fMYFKI4oYTmohPbuv5DsGl3crXkEtoWfwtezWDI3x3Os_Zz69fflxdi9vv326uLm-FUbpJotZ9PfXKVCOoqZMIk5Z13chx1mqrOtm2Y42IvZ6hkHXbtFVnFEzFMBoclTpnn45zDzH8yUhpWCwZdO74TUMrZdPoqitCcRSaGIgizsMh2gXiOlRyeGxvKO0NBR7bK_oPp8F5XHB6Vp_qKvzHEw9kwM0RvLH0LKt1eYVq1T9ONqj4</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>NIJLAND, E. A</creator><creator>STRASBURGER, C. J</creator><creator>POPP-SNIJDERS, C</creator><creator>VAN DER WAL, P. S</creator><creator>VAN DER VEEN, E. A</creator><general>Portland Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981001</creationdate><title>A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men</title><author>NIJLAND, E. A ; STRASBURGER, C. J ; POPP-SNIJDERS, C ; VAN DER WAL, P. S ; VAN DER VEEN, E. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-2492d93c1ba3d80ead402260bf43538077b2eee94fa0ea276718c3adc1bbceb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Hormones. Endocrine system</topic><topic>Human Growth Hormone - blood</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Insulin-Like Growth Factor Binding Protein 3 - blood</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - pharmacology</topic><topic>Osteocalcin - blood</topic><topic>Pharmacology. Drug treatments</topic><topic>Prolactin - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NIJLAND, E. A</creatorcontrib><creatorcontrib>STRASBURGER, C. J</creatorcontrib><creatorcontrib>POPP-SNIJDERS, C</creatorcontrib><creatorcontrib>VAN DER WAL, P. S</creatorcontrib><creatorcontrib>VAN DER VEEN, E. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NIJLAND, E. A</au><au>STRASBURGER, C. J</au><au>POPP-SNIJDERS, C</au><au>VAN DER WAL, P. S</au><au>VAN DER VEEN, E. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men</atitle><jtitle>European journal of endocrinology</jtitle><addtitle>Eur J Endocrinol</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>139</volume><issue>4</issue><spage>395</spage><epage>401</epage><pages>395-401</pages><issn>0804-4643</issn><eissn>1479-683X</eissn><abstract>The synthetic hexapeptide growth hormone-releasing peptide (GHRP)-2 specifically stimulates GH release in man. To determine the effects of prolonged treatment and whether response attenuation occurs in man, we administered to nine healthy subjects a daily s.c. injection of 100 microg GHRP-2 over 5 days. Every day blood samples were taken to determine GH, IGF-I, IGF-binding protein (IGFBP)-3 and osteocalcin levels. On days 1,3 and 5, GH was measured at -20,0,20,40,60,90,120 and 180 min using an immunometric and an immunofunctional assay. Mean-/+S.D). peak GH concentrations were 83+/-31, 59+/-22 and 51+/-13 microg/l on days 1, 3 and 5 respectively. Mean+/-S.D. areas under the curve for days 1, 3 and 5 were 6366+/-2514, 3987 +/- 1418 and 3392+/-1215 mU/l per min. Despite the maintained GH release, analysis of variance revealed that significant response attenuation occurred (P < 0.01). Mean serum IGF-I concentration did not increase after a 5 day treatment with GHRP-2. Mean basal levels were 22, 25,23,25,23,24 nmol/l measured on days 1 to 6. However, osteocalcin, another serum marker of GH activity in tissue, increased significantly from 3.2+/-1.0 to 4.2+/-0.4 microg/l (mean+S.D.) (P< 0.01).</abstract><cop>Colchester</cop><pub>Portland Press</pub><pmid>9820615</pmid><doi>10.1530/eje.0.1390395</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0804-4643 |
| ispartof | European journal of endocrinology, 1998-10, Vol.139 (4), p.395-401 |
| issn | 0804-4643 1479-683X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70066418 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Adult Biological and medical sciences Hormones. Endocrine system Human Growth Hormone - blood Humans Hydrocortisone - blood Insulin-Like Growth Factor Binding Protein 3 - blood Insulin-Like Growth Factor I - metabolism Kinetics Male Medical sciences Oligopeptides - administration & dosage Oligopeptides - pharmacology Osteocalcin - blood Pharmacology. Drug treatments Prolactin - blood |
| title | A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A01%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20five%20day%20treatment%20with%20daily%20subcutaneous%20injections%20of%20growth%20hormone-releasing%20peptide-2%20causes%20response%20attenuation%20and%20does%20not%20stimulate%20insulin-like%20growth%20factor-I%20secretion%20in%20healthy%20young%20men&rft.jtitle=European%20journal%20of%20endocrinology&rft.au=NIJLAND,%20E.%20A&rft.date=1998-10-01&rft.volume=139&rft.issue=4&rft.spage=395&rft.epage=401&rft.pages=395-401&rft.issn=0804-4643&rft.eissn=1479-683X&rft_id=info:doi/10.1530/eje.0.1390395&rft_dat=%3Cproquest_cross%3E70066418%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70066418&rft_id=info:pmid/9820615&rfr_iscdi=true |